Single Dose of SHR-1222, a Sclerostin Monoclonal Antibody, in Healthy Men and Postmenopausal Women With Low Bone Mass: A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation, Phase I Study

• Main Authors: Zhijie Dai (Author), Pingfei Fang (Author), Xiang Yan (Author), Ronghua Zhu (Author), Qiong Feng (Author), Qiangyong Yan (Author), Lingfeng Yang (Author), Xiao Fan (Author), Yuting Xie (Author), Lihong Zhuang (Author), Sheng Feng (Author), Yantao Liu (Author), Sheng Zhong (Author), Zeyu Yang (Author), Zhifeng Sheng (Author), Zhiguang Zhou (Author)
• Format: Book
• Published: Frontiers Media S.A., 2021-10-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

SHR-1222 is a humanized monoclonal antibody targeting sclerostin and has the potential to promote bone formation and reduce bone resorption. This study was aimed to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of SHR-1222 in healthy men and postmenopausal w...